Anti-survivin antibody responses in lung cancer

Karanikas, Vaios; Khalil, Sanaa; Kerenidi, Theodora; Gourgoulianis, Konstantinos; Germenis, Anastasios E.

doi:10.1016/j.canlet.2009.03.015

Cited by 14 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody reactivity against recombinant full-length human survivin fused to calmodulin (CaM)-tag (BIRC5, Abcam) was measured by DAC-ELISA as described previously (16) and by sandwich ELISA. To validate that both assays detected survivin autoantibodies and to assess their dynamic ranges, we used a rabbit monoclonal antibody (mAb) to survivin (0.06-10,00 ng/mL; Abcam) to establish standard curves ( Supplementary Fig.…”

Section: Detection Of Anti-survivin Antibodies By Elisamentioning

confidence: 99%

“…S1). To determine if these assays could distinguish human autoantibody-positive from -negative sera, we analyzed serum from 7 NSCLC patients that had been previously reported (16) to be positive for survivin autoantibodies and from 7 healthy nonsmoking control subjects, the type of control group used by Karanikas and colleagues (16). The replicability of our sandwich ELISA was established by repeatedly testing a single sample for intra-assay variation, as well as testing inter-assay variation.…”

Section: Detection Of Anti-survivin Antibodies By Elisamentioning

confidence: 99%

“…Antibodies to survivin are one of the autoantibodies described most frequently in lung cancer (5,(11)(12)(13)(14)(15)(16)(17)(18). Survivin, also known as baculoviral IAP repeat-containing protein 5 (BIRC5), is a member of the inhibitor apoptosis proteins (IAP) family.…”

Section: Introductionmentioning

confidence: 99%

“…For that purpose, we collected, NSCLC cases from the NELSON trial with well-matched controls to the NSCLC cases, subdivided into individuals who were currently smoking or were former smokers. In addition, we included late-stage NSCLC patients from the Dutch Association of Pulmonologists for Lung Diseases and Tuberculosis (NVALT)-12 study (22) and a control group of generally healthy blood donors, similar to that used in the publications on survivin autoantibodies (5,(11)(12)(13)(14)(15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

“…All published studies on survivin autoantibodies in lung cancer have used the direct antigen-coating (DAC) form of an ELISA with a recombinant survivin (5,(11)(12)(13)(14)(15)(16)(17)(18). However, the DAC-ELISA assay can give false-positive results if antibodies bind to impurities in the antigen preparation.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Broodman

VanDuijn

Stingl

et al. 2016

Cancer Immunology Research

Self Cite

View full text Add to dashboard Cite

The high mortality rate in lung cancer is largely attributable to late diagnosis. Case-control studies suggest that autoantibodies to the survivin protein are potential biomarkers for early diagnosis. We tested the hypothesis that sandwich ELISA can detect autoantibodies to survivin before radiologic diagnosis in patients with early-stage non-small cell lung cancer (NSCLC). Because previous studies assayed survivin autoantibodies with the direct antigencoating ELISA (DAC-ELISA), we first compared that assay with the sandwich ELISA. Based on the more robust results from the sandwich ELISA, we used it to measure survivin autoantibodies in the serum of 100 individuals from a well-controlled population study [the Dutch-Belgian Lung Cancer Screening Trial (NELSON) trial] composed of current and former smokers (50 patients with NSCLC, both before and after diagnosis, and 50 matched, smoking-habit control subjects), and another 50 healthy nonsmoking control subjects. We found no difference in specific autoantibodies to survivin in NSCLC patients, although nonspecific median optical densities were 24% higher (P < 0.001) in both NSCLC patients and smokers, than in healthy nonsmokers. Finally, we confirmed the ELISA results with Western blot analysis of recombinant and endogenous survivin (HEK-293), which showed no anti-survivin reactivity in patient sera. We conclude that specific anti-survivin autoantibody reactivity is most likely not present in sera before or after diagnosis. Autoantibody studies benefit from a comparison to a well-controlled population, stratified for smoking habit.

show abstract

Section: Detection Of Anti-survivin Antibodies By Elisamentioning

confidence: 99%

Section: Detection Of Anti-survivin Antibodies By Elisamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Broodman

VanDuijn

Stingl

et al. 2016

Cancer Immunology Research

Self Cite

View full text Add to dashboard Cite

show abstract

Plasma anti‐BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer

et al. 2018

View full text Add to dashboard Cite

A recent study demonstrated that circulating levels of IgG antibodies against linear peptide antigens derived from baculoviral IAP repeat‐containing protein 5 isoform 2 ( BIRC 5) and myc proto‐oncogene protein ( MYC ) were significantly increased in nonsmall cell lung cancer ( NSCLC ). This study was undertaken to replicate this initial work in an independent sample. An enzyme‐linked immunosorbent assay ( ELISA ) was developed in‐house to examine plasma IgG antibodies for three linear peptide antigens derived from BIRC 5a, BIRC 5b, and MYC in 211 patients with NSCLC and 200 control subjects. A Mann–Whitney U ‐test demonstrated that plasma anti‐ BIRC 5a IgG levels, but not anti‐ BIRC 5b or anti‐ MYC IgG levels, were significantly higher in NSCLC patients than control subjects, especially in male patients. Both squamous cell cancer and adenocarcinoma showed increased anti‐ BIRC 5a IgG levels, but the IgG levels were not found to be changed significantly in the early stage of NSCLC . Kaplan–Meier survival analysis showed that NSCLC patients with high anti‐ BIRC 5b IgG levels had better prognosis and longer overall survival ( OS ) than patients with low anti‐ BIRC 5b IgG levels, although this significant difference failed to survive the adjustment for age, gender, NSCLC stages, and types. Plasma anti‐ BIRC 5a and MYC IgG levels did not show significant associations with OS . In conclusion, Plasma anti‐ BIRC 5 IgG may be a useful marker for assessment of prognosis of NSCLC but not for early diagnosis of this malignancy.

show abstract

The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer

et al. 2013

View full text Add to dashboard Cite

Anti-survivin antibody responses in lung cancer

Cited by 14 publications

References 29 publications

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

Plasma anti‐BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer

The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer

Contact Info

Product

Resources

About